An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

Lynda Vuong(Memorial Sloan Kettering Cancer Center), Alison C. MacKinnon(Galecto (Denmark))
Cancer Research
January 23, 2019
Cited by 140


Related Papers